Multicenter, Safety Follow-Up Study to Assess Safety of Prior Treatment with Romosozumab in Children and Adolescents with Osteogenesis Imperfecta

Erik Imel, MD

Principal Investigator

Status: Enrolling By Invitation Ages: 0 Years - 17 Years Gender: All Genders Phase: N/A 1 Locations

Brief Description

To evaluate the safety of romosozumab in participants with osteogenesis imperfecta (OI) that have completed Study 20200105, regardless of whether they received investigational product (romosozumab) until the last protocol-specified dose or ended investigational product early

Eligibility of study

Completion of the Romosozumab arm in the 20200105 Amgen Pediatric OI Trial

Interested in participating?

Enrollment in IU School of Medicine clinical trials is managed through our All IN for Health program. Many studies only accept people who are part of an invited group. Visit allinforhealth.info to connect with the study team, or contact your doctor to see if you are eligible.

Connect with the study team